Search results
Results from the WOW.Com Content Network
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
After a series of clinical trials in 2004, Avastin was approved by the FDA, becoming the first commercially available anti-angiogenesis drug. FDA approval of Avastin for breast cancer treatment was later revoked on November 18, 2011.
In 2004, the first angiogenesis inhibitor, bevacizumab (Avastin), was approved by the FDA, as a treatment for colon cancer. It is a recombinant humanized monoclonal antibody that was discovered and developed by Napoleone Ferrara, a scientist at Genentech. [17] [18] A similar drug, Lucentis, was later approved for treating macular degeneration. [3]
Avastin was given an accelerated approval for the indication, which allows the drug to be marketed with. What the FDA giveth, the FDA can taketh away. A few weeks ago, the FDA yanked Roche's right ...
If the FDA follows its advisory panel's recommendation from last month, it may revoke its approval of Avastin for the. Roche's (RHHBY) blockbuster cancer drug, Avastin, is up for review by the U.S ...
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials ...
In 2009, Avastin gained its fifth approval for treatment of glioblastoma multiforme, and sixth approval for the treatment of metastatic renal cell carcinoma. It was most publicized for its approval in advanced breast cancer treatment, but the FDA approval for breast cancer treatment was subsequently revoked in November 2011.
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...